DAX25.378 +0,5%Est506.009 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,21 +1,4%Nas23.671 ±0,0%Bitcoin78.042 -0,1%Euro1,1678 +0,4%Öl63,21 +0,3%Gold4.620 +2,4%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 Bayer BAY001 TKMS thyssenkrupp Marine Systems TKMS00 DroneShield A2DMAA Allianz 840400 RENK RENK73 Amazon 906866 BASF BASF11 Siemens Energy ENER6Y Lufthansa 823212 Infineon 623100 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas höher -- Wall Street uneins -- Eli Lilly plant wohl Abivax-Übernahme -- NVIDIA, VW, Mercedes, Novo Nordisk, Rüstungsaktien, Amazon, DroneShield, Airbus, BYD im Fokus
Top News
Hot Stocks heute: Trade der Woche: Bereich um 25.500 Punkte - Discount Short (PK2NVK) Hot Stocks heute: Trade der Woche: Bereich um 25.500 Punkte - Discount Short (PK2NVK)
TKMS: Strategischer Durchbruch in Indien - ein 8 Mrd. Euro-Auftrag bahnt sich an! TKMS: Strategischer Durchbruch in Indien - ein 8 Mrd. Euro-Auftrag bahnt sich an!
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Zenas BioPharma Aktie

Kaufen
Verkaufen
19,40 USD +3,26 USD +20,20 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.738,57 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA40MUX

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS98937L1052

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolZBIO

Zenas BioPharma Aktien News

DatumMeistgelesen
TraderFoxAktien on FireZenas Biopharma: 56 % Wirksamkeit in der Phase-3-Studie INDIGO waren nicht genug - CEO nutzt Verkaufspanik für ein 1,6-Mio.-USD-Investment
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
BenzingaZenas BioPharma Touts Phase 3 Win, But Stock Crashes
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
PR NewswireSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)
finanzen.netZenas BioPharma: Bilanzzahlen zum vergangenen Quartal
TraderFoxKurszieleTOP-5-Kursziele der Analysten am 28.10.25
Dow JonesMÄRKTE USA/Fest - Neue KI-Chips beflügeln Qualcomm
Dow JonesMÄRKTE USA/Rekordlauf geht weiter - Technologieaktien favorisiert
MotleyFoolChairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
BenzingaZenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
finanzen.netZenas BioPharma legte die Bilanz zum abgelaufenen Quartal vor
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireInvestors who lost money on Zenas BioPharma, Inc.(ZBIO) should contact The Gross Law Firm about pending Class Action - ZBIO
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
PR NewswireZenas BioPharma, Inc. Class Action: Levi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireShareholders that lost money on Zenas BioPharma, Inc.(ZBIO) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
PR NewswireINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
PR NewswireShareholders of Zenas BioPharma, Inc. Should Contact The Gross Law Firm Before June 16, 2025 to Discuss Your Rights - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
PR NewswireZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How to Lead the Class Action Against Zenas BioPharma, Inc.
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireZBIO Deadline: ZBIO Investors with Losses in Excess of $100K Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
finanzen.netZenas BioPharma: So viel setzte das Unternehmen zuletzt um
PR NewswireLevi & Korsinsky Reminds Zenas BioPharma, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Lawsuit Filed by The Rosen Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
PR NewswireLevi & Korsinsky Notifies Shareholders of Zenas BioPharma, Inc.(ZBIO) of a Class Action Lawsuit and an Upcoming Deadline
PR NewswireZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO

Zenas BioPharma News

Zenas BioPharma News: auf dieser Seite finden Sie alle Zenas BioPharma News und Nachrichten zur Zenas BioPharma Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Zenas BioPharma News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Zenas BioPharma News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.